<- Go Home
Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Market Cap
CAD 296.0M
Volume
29.2K
Cash and Equivalents
CAD 48.0M
EBITDA
CAD 12.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CAD 18.0M
Profit Margin
81.08%
52 Week High
CAD 14.50
52 Week Low
CAD 3.02
Dividend
N/A
Price / Book Value
3.14
Price / Earnings
12.76
Price / Tangible Book Value
3.88
Enterprise Value
CAD 248.3M
Enterprise Value / EBITDA
20.42
Operating Income
CAD 11.0M
Return on Equity
28.43%
Return on Assets
7.90
Cash and Short Term Investments
CAD 48.0M
Debt
CAD 296.0K
Equity
CAD 88.8M
Revenue
CAD 22.2M
Unlevered FCF
CAD 5.5M
Sector
Pharmaceuticals
Category
N/A